The Prognostic and Clinicopathological Roles of Sirtuin-3 in Various Cancers.
The Prognostic and Clinicopathological Roles of Sirtuin-3 in Various Cancers.
复制标题
Sirtuin-3 在各种癌症中的预后和临床病理学作用
DOI：
10.1371/journal.pone.0159801
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Xu YM
中科院分区：
文献类型：
--
作者：
Yu FY;Xu Q;Wu DD;Lau AT;Xu YM
Sirtuin-3（SIRT 3）是一种主要的线粒体NAD（+）依赖性脱乙酰酶，在人类癌症的进展和发展中起着关键作用。尽管不同的研究小组已经研究了SIRT 3在各种癌症中表达的预后和临床病理学特征，但是，可以观察到不一致和相反的结果。因此，在这项研究中，我们进行了荟萃分析，以评估SIRT 3表达在各种癌症中的意义。截至2015年11月，在PubMed、Embase、中国知网和万方数据中进行了系统性文献检索。进行总效应分析和亚组分析，以评估SIRT 3表达与各种癌症患者的总生存期、癌/非癌组织、淋巴结转移、病理分化、肿瘤淋巴结转移（TNM）分期、肿瘤大小和性别之间的关系。计算风险比（HR）或比值比（OR）及95%置信区间（CI），以阐明风险或风险相关性。共纳入14项研究，包括2165例癌症患者，以评估SIRT 3免疫组化表达与总生存率或临床病理特征之间的关系。SIRT 3的表达与胃癌的总生存率显著相关（HR = 0.62，95%CI = 0.43-0.89，P = 0.009）和肝细胞癌患者（HR = 0.56，95%CI = 0.42-0.74，P<0.0001），肝癌患者癌/非癌组织（OR = 0.04，95%CI = 0.01-0.16，P<0.0001），乳腺癌患者淋巴结转移（OR = 2.20，95%CI = 1.49-3.26，P<0.0001），与肝细胞癌患者的病理分化程度有关胃癌患者OR = 0.33，95% CI = 0.21-0.50，P<0.00001。总效应分析显示SIRT 3表达与病理分化程度显著相关（OR = 0.46，95%CI = 0.29-0.74，P = 0.001）。SIRT 3的表达与其他临床病理参数之间无明显相关性，提示SIRT 3的表达水平与特定肿瘤的预后和临床特征相关。
Sirtuin-3 (SIRT3) is a major mitochondrial NAD(+)-dependent deacetylase and plays a key role in the progression and development of human cancers. Although the prognostic and clinicopathological features of SIRT3 expression in various cancers have been investigated by different research groups, however, inconsistent and opposing results can be observed. In this study, we therefore performed a meta-analysis to evaluate the significance of SIRT3 expression in various cancers. Systematic literature searching was performed in PubMed, Embase, China National Knowledge Infrastructure, and Wanfang Data up to November 2015. Total effect analyses and subgroup analyses were performed to evaluate the relationship between SIRT3 expression and overall survival, cancer/non-cancer tissues, lymph node metastasis, pathological differentiation, tumor node metastasis (TNM) stage, tumor size, and gender, in various cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to clarify the risk or hazard association. A total of 14 studies comprising 2165 cancer patients were included to assess the association between SIRT3 immunohistochemical expression and overall survival or clinicopathological characteristics. SIRT3 expression was significantly associated with overall survival in gastric cancer (HR = 0.62, 95% CI = 0.43–0.89, P = 0.009) and hepatocellular carcinoma patients (HR = 0.56, 95% CI = 0.42–0.74, P<0.0001), cancer/non-cancer tissues in hepatocellular carcinoma patients (OR = 0.04, 95% CI = 0.01–0.16, P<0.0001), lymph node metastasis in breast cancer patients (OR = 2.20, 95% CI = 1.49–3.26, P<0.0001), and also pathological differentiation in hepatocellular carcinoma patients (OR = 0.69, 95% CI = 0.48–0.98, P = 0.04) and gastric cancer patients (OR = 0.33, 95% CI = 0.21–0.50, P<0.00001), by subgroup analyses. Furthermore, SIRT3 expression was significantly associated with pathological differentiation in total effect analysis (OR = 0.46, 95% CI = 0.29–0.74, P = 0.001). No detectable relation between SIRT3 expression and other clinicopathological parameters were found. This meta-analysis indicates that SIRT3 expression level is associated with prognostic and clinical features in specific cancers.